Literature DB >> 28072551

Assessment of subclinical left ventricular changes in essential hypertensive patients with hyperuricemia: A three-dimensional speckle-tracking echocardiography study.

Xiaoyan Fang1, Cuizhen Pan1, Yongle Chen1, Minmin Sun1, Zhuojun Zhang2, Lindi Jiang2, Xiaolin Wang3, Xianhong Shu1.   

Abstract

OBJECTIVE: To evaluate the effect of hyperuricemia (HU) on subclinical changes of left ventricle (LV) function and structure in patients with hypertension (HT) using three-dimensional speckle-tracking echocardiography (3DSTE) and to explore the relationships between serum uric acid (SUA) levels and three-dimensional speckle tracking echocardiography (3DSTE) parameters in hypertensive and nonhypertensive patients with HU.
METHODS: Four age- and sex-matched groups were studied: I: healthy controls, HT- HU- (n = 40); II: HT- HU+ (n = 40); III: HT+ HU- (n = 40); IV: HT+ HU+ (n = 44). Conventional echocardiography and 3DSTE were recorded. Relative wall thickness (RWT) and left ventricular mass index assessed by M-mode echocardiography (LVMi-M) were calculated. 3DSTE parameters including LV volumes and ejection fraction (EF), LVMi-3D, global longitudinal strain (GLS), and global circumferential strain (GCS) were compared. The relationships between SUA levels and 3DSTE parameters were investigated.
RESULTS: Despite LV diameters, LV volumes and EF were similar among groups (all p > 0.05), GLS decreased and LVMi-3D increased from controls (group I) to patients with HU or HT alone (group II or III), and patients with both HU and HT (group IV) (all p < 0.05). SUA levels were significantly correlated with the absolute value of GLS (r = -0.461, p < 0.05) and LVMi-3D (r = 0.504, p < 0.05) in hypertensive and nonhypertensive patients with HU.
CONCLUSIONS: HU may exacerbate LV systolic dysfunction and remodeling in hypertensive patients, which can be detected by 3DSTE. Early uric acid lowing treatment may be beneficial for hypertensive patients with HU.

Entities:  

Keywords:  Hypertension; hyperuricemia; left ventricular; speckle-tracking; three-dimensional

Mesh:

Substances:

Year:  2017        PMID: 28072551     DOI: 10.1080/10641963.2016.1210626

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  2 in total

1.  Comparison between febuxostat and allopurinol uric acid-lowering therapy in patients with chronic heart failure and hyperuricemia: a multicenter randomized controlled trial.

Authors:  Satoshi Suzuki; Akiomi Yoshihisa; Tetsuro Yokokawa; Atsushi Kobayashi; Takayoshi Yamaki; Hiroyuki Kunii; Kazuhiko Nakazato; Akihiro Tsuda; Tatsunori Tsuda; Toshiyuki Ishibashi; Ichiro Konno; Osamu Yamaguchi; Hirofumi Machii; Naoki Nozaki; Takeshi Niizeki; Takuya Miyamoto; Yasuchika Takeishi
Journal:  J Int Med Res       Date:  2021-12       Impact factor: 1.671

2.  Selected matrix metalloproteinases activity and hypertension-mediated organ damage in relation to uric acid serum level.

Authors:  Krystian Gruszka; Marek Rajzer; Tomasz Drożdż; Wiktoria Wojciechowska; Tomasz Pizoń; Kamila Migacz-Gruszka; Danuta Czarnecka
Journal:  Cardiol J       Date:  2019-04-17       Impact factor: 2.737

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.